Posts By: iTakeControl

Join our team as a Testing and Support Associate

by iTakeControl • July 12, 2021

Testing and Support Associate About iTakeControl, a Red Nucleus company iTakeControl is a mClinical research, real world evidence, and mobile application company for the biopharma and life science organizations. We offer a comprehensive suite of clinical services and technology: real world evidence planning, mobile clinical trial data, and clinical operations services. The company is formed […]


Join our team as a Clinical Operations Manager

by iTakeControl • July 12, 2021

Clinical Operation Manager   About iTakeControl, a Red Nucleus company  iTakeControl is a mHealth and mClinical real world evidence and mobile application for the biopharma and life science organizations. We offer a comprehensive suite of real world evidence services and tools: real world evidence planning, mobile clinical trial data, mobile learning and training for biopharma compliance, and open science, real world mobile health apps for […]


Webinar: Video Recording of Clinical Assessments at Home or In Clinic

by iTakeControl • June 30, 2021

Watch the iTakeControl Webinar on: “Video Recording of Clinical Assessments at Home or In Clinic” Presented on June 29th, 2021 Click here to get access. Get in touch for more information.


Designing a Virtual Long Term Registry in Rare Diseases

by iTakeControl • April 6, 2021

Watch the iTakeControl presentation at the Real World Evidence Conference on: “Designing a Virtual Long Term Registry in Rare Diseases” Presented on March 23rd, 2021 Click here to get access. Get in touch for more information.


iTakeControl Health Joins Red Nucleus

by iTakeControl • March 4, 2021

iTakeControl video, virtual trial, and ePRO products and services expands Red Nucleus into clinical research space. Boston, MA – March 4 2021 – iTakeControl (ITC), a leading provider of clinical operations and medical affairs technology and services focused on rare disease and specialty pharma, announces that it has been acquired by Red Nucleus, a premier […]


Webinar: Considerations for Conducting a 6 Minute Walk Test at Home

by iTakeControl • September 28, 2020

Watch the iTakeControl team’s webinar on: “Considerations for Conducting a 6 Minute Walk Test at Home” Presented on September 16th, 2020 Click here to get access. Get in touch for more information.


Covid-19 A Home Logo

New Public Health Study Launches for At-Home COVID-19 Patient Experiences

by iTakeControl • August 11, 2020

Boston MA – iTakeControl Health is launching a new public health study, the COVID-19 @Home Patient Survey, for individuals who had COVID-19 and managed their illness and treatment primarily at home. The mobile-based IRB approved study is open to anyone 18 years of age or older with a suspected or confirmed case of COVID-19. The […]


Webinar on Virtual Trials!

by iTakeControl • April 23, 2020

Watch the iTakeControl and Casimir teams webinar on: “Transitioning Clinical Trials From Site-Based To Site-Less Virtual Trials Using Video Capture.” Presented on April 23rd, 2020 Click here to get access. Get in touch for more information.


Adapting traditional content validation methods to fit purpose: an example with a novel video assessment and training materials in Duchenne muscular dystrophy (DMD)

by iTakeControl • July 13, 2019

Abstract Purpose The Duchenne muscular dystrophy (DMD) Video Assessment requires a caregiver to record six videos of their ambulatory child performing physical activities using a smartphone application (app). Innovative assessments that combine a performance measure, technology, and an observer require new approaches to content validation studies. This study presents a novel approach to establish the […]


The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview.

by iTakeControl • June 1, 2019

Check out a paper written by our partners Casimir Trials on the use of videos captured using iTakeControl’s platform Abstract INTRODUCTION: The traditional model of evaluating treatments based primarily on primary outcome measures has stumbled in its application to rare disease. Rare disease clinical trials face the methodological challenges of small, heterogeneous patient populations and […]